12:02 PM
 | 
Oct 27, 2017
 |  BC Week In Review  |  Financial News  |  Completed Offerings

ADC raises $200M private placement

On Oct. 23, antibody-drug conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics Management, Redmile, the Wild Family Office and AstraZeneca plc (LSE:AZN; NYSE:AZN).

Next year, ADC Therapeutics plans to start registrational trials of lead candidates ADCT-301 (HuMax-TAC-ADC)...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >